Overalls

GRIST Consulting Celebrates the Winners of its GRIST Service Excellence and Sales Excellence Awards from the Auscontact National Awards

Retrieved on: 
Friday, March 1, 2024

GRIST Consulting , a change management consultancy that specialises in the people-side of change, is excited to celebrate the winners of its GRIST Service Excellence and Sales Excellence Awards from the Auscontact National Awards that recognised customer-centric behaviours demonstrated by consultants in service and sales contact centres.

Key Points: 
  • GRIST Consulting , a change management consultancy that specialises in the people-side of change, is excited to celebrate the winners of its GRIST Service Excellence and Sales Excellence Awards from the Auscontact National Awards that recognised customer-centric behaviours demonstrated by consultants in service and sales contact centres.
  • The GRIST Service Excellence and Sales Excellence Awards utilised judging that was based on a unique, objective, behavioural assessment of the customer service experience by assessing key behaviours linked to real-world outcomes.
  • “A huge congratulations to our finalists – it was fantastic to see you all at the awards!” said a spokesperson for GRIST Consulting.
  • By consistently providing a specific solution and explaining its features, customer expectations are met, giving consultants the confidence to ask for the sale,” furthered the spokesperson from GRIST Consulting.

Unleashing The Power Of Red Light Therapy For Skincare

Retrieved on: 
Thursday, February 29, 2024

It is undoubtedly because of the limitless potential of Red Light therapy that leading companies such as Bestqool have launched Red Light Therapy devices that people can buy and easily use from within the comfort of their homes.

Key Points: 
  • It is undoubtedly because of the limitless potential of Red Light therapy that leading companies such as Bestqool have launched Red Light Therapy devices that people can buy and easily use from within the comfort of their homes.
  • Exploring the Benefits of Red Light Therapy for Skincare:
    It was not a long time ago that Red Light Therapy was introduced as a means of reducing pain intensity and accelerating the repair of damaged and injured tissues.
  • Incorporating Red Light Therapy into Your Skincare Routine:
    It must be heartening to know for all die-hard skincare enthusiasts that to achieve the best results related to skincare, the key is consistency.
  • Precautions and Potential Side Effects:
    On one hand, while there are several benefits and advantages of Red Light Therapy for you, there is also one side that highlights the negative side or the side effects of Red Light Therapy for the skin.

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

Retrieved on: 
Thursday, February 29, 2024

We currently expect cash and cash equivalents to be sufficient to fund operations into the first half of 2027.

Key Points: 
  • We currently expect cash and cash equivalents to be sufficient to fund operations into the first half of 2027.
  • R&D Expenses: Research and development expenses were $97.1 million for 2023, as compared to $80.3 million for 2022.
  • G&A Expenses: General and administrative expenses were $36.5 million for 2023, as compared to $32.9 million for 2022.
  • Net Loss: Net loss was $100.8 million for 2023, as compared to net loss of $107.5 million for 2022.

ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, February 28, 2024

ET

Key Points: 
  • ET
    RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its fourth quarter and full year 2023 financial results and provided a business update.
  • “We are pleased with our 2023 performance, which marked first-time positive adjusted net income on a full year basis.
  • We believe our unwavering focus on the immune deficient patient segment has allowed ADMA to establish itself as a premier provider of specialty biologics.
  • Fourth Quarter 2023 Financial Results:
    Total revenues were $73.9 million for the quarter ended December 31, 2023, as compared to $50.0 million for the quarter ended December 31, 2022, an increase of $23.9 million, or approximately 48%.

Milestone Scientific Commences Direct Sales of STA Single Tooth Anesthesia System® with Meridian Endo & Perio

Retrieved on: 
Wednesday, February 28, 2024

ROSELAND, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announces it has commenced direct sales of its STA Single Tooth Anesthesia System® (STA) with Meridian Endo & Perio , a large endodontics, periodontics and implant dentistry practice with three offices in Wisconsin.

Key Points: 
  • ROSELAND, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announces it has commenced direct sales of its STA Single Tooth Anesthesia System® (STA) with Meridian Endo & Perio , a large endodontics, periodontics and implant dentistry practice with three offices in Wisconsin.
  • Dr. Lisa Teel, periodontist and implant surgeon with Meridian Endo and Perio, stated, “Our practice is committed to adopting the latest technologies to improve the overall patient experience.
  • Upon introduction, we were struck by the ease of use, as well as the STA’s ability to put patients at ease with dental anesthesia.
  • Moreover, we appreciate the ongoing educational and training support provided by Milestone Scientific.”
    Arjan Haverhals, Chief Executive Officer of Milestone Scientific, commented, “This latest agreement illustrates the benefits of our new direct sales model.

FreeWire Ushers New Era of EV Charging & Energy Management with Launch of Boost Power Pro

Retrieved on: 
Tuesday, February 27, 2024

Newark, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- FreeWire Technologies, the leading provider of battery-integrated electric vehicle (EV) charging stations and energy management solutions, today announced Boost Power Pro, the flagship offering within FreeWire’s latest product line, the Pro Series.

Key Points: 
  • Newark, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- FreeWire Technologies, the leading provider of battery-integrated electric vehicle (EV) charging stations and energy management solutions, today announced Boost Power Pro, the flagship offering within FreeWire’s latest product line, the Pro Series.
  • Simultaneous Charging: While simultaneous charging has been a staple feature of FreeWire products, the Pro Series elevates this capability.
  • This not only aids in stabilizing the power grid during crucial times but also provides financial incentives to Boost Power Pro owners.
  • The Boost Power Pro and Boost Charger Pro can be reserved today and will feature both CCS and NACS connector optionality.

Tower Semiconductor and Tianyi Micro Announce Strategic Cooperation in Development of Next Generation OLED Micro Displays for AR/VR

Retrieved on: 
Monday, February 26, 2024

The development is based on Tower’s unique 180nm and 65nm dedicated micro display backplane process flows, supporting current-driven (as opposed to voltage-driven) OLED pixel designs.

Key Points: 
  • The development is based on Tower’s unique 180nm and 65nm dedicated micro display backplane process flows, supporting current-driven (as opposed to voltage-driven) OLED pixel designs.
  • Tianyi Micro is currently the sole provider in China of current-driven pixel designs and selected Tower as its key foundry partner for micro display backplane developments.
  • Having such dedicated flows enables Tianyi to pursue its leading market position with next-generation micro displays.
  • For additional information about Tower Semiconductor’s micro displays technology offerings, please visit here.

AXT, Inc. Announces Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Thursday, February 22, 2024

Revenue for the fourth quarter of 2023 was $20.4 million, compared with $17.4 million in the third quarter of 2023 and $26.8 million for the fourth quarter of 2022.

Key Points: 
  • Revenue for the fourth quarter of 2023 was $20.4 million, compared with $17.4 million in the third quarter of 2023 and $26.8 million for the fourth quarter of 2022.
  • GAAP gross margin was 22.6 percent of revenue for the fourth quarter of 2023, compared with 10.7 percent of revenue in the third quarter of 2023 and 32.1 percent for the fourth quarter of 2022.
  • This compares with $8.6 million in the third quarter of 2023 and $9.6 million for the fourth quarter of 2022.
  • Fiscal Year 2023 Results (January 1 to December 31, 2023)
    Revenue for fiscal year 2023 was $75.8 million, compared with $141.1 million in fiscal year 2022.

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Retrieved on: 
Thursday, February 22, 2024

WALTHAM, Mass. and BOULDER, Colo., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported positive Part 1b data from the Company’s ongoing SUMMIT trial evaluating bezuclastinib in patients with nonadvanced systemic mastocytosis (NonAdvSM) at the 2024 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) meeting taking place February 23-26, 2024 in Washington, D.C.

Key Points: 
  • “The magnitude and speed of symptomatic reductions, along with corresponding improvements in quality-of-life, reported by patients in SUMMIT Part 1b has not been seen previously with other treatment options in this patient population.
  • Thirty-four patients in Part 1b were treated with either bezuclastinib or placebo plus best supportive care.
  • Patients were enrolled with the following sub-types: 33 patients with indolent systemic mastocytosis (ISM) and one patient with smoldering systemic mastocytosis (SSM).
  • Thirty-four patients enrolled in SUMMIT Part 1b were evaluated for signs of clinical activity over 12 weeks, including well-accepted biomarkers of disease burden.

White Gold Corp. Discovers 1 km Long Gold-In-Soil Anomaly 9 km Northwest of Its VG Deposit, White Gold District, Yukon, Canada

Retrieved on: 
Thursday, February 22, 2024

The new soil geochemical anomaly appears to be similar in character to the VG deposit and the Golden Saddle deposit which form part of the Company’s flagship White Gold Project.

Key Points: 
  • The new soil geochemical anomaly appears to be similar in character to the VG deposit and the Golden Saddle deposit which form part of the Company’s flagship White Gold Project.
  • The strike length, continuity, and similarities of the soil anomaly relative to the surface geochemical signatures of our Golden Saddle and VG deposits represents an exciting new target.
  • The soil sampling program consisted of approximately 200 samples collected at 50 m sample spacings on 100 m-spaced survey lines.
  • The principal gold anomaly is localized at this fault intersection, associated with a semi-circular magnetic high approximately 1 km in diameter.